Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human
Author: ["José M.P. Freije","Julia A. Lawrence","Melinda G. Hollingshead","Abel De La Rosa","Ven Narayanan","Michael Grever","Edward A. Sausville","Kenneth Paull","Patricia S. Steeg"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
We have used the COMPARE computer algorithm and Nm23 expression as a marker of tumor metastatic potential to examine the in vitro antiproliferative activity of chemotherapeutic drugs on human breast carcinoma and melanoma cell lines. None of 171 compounds in clinical use or under development and only 40 of 30,000 repository compounds exhibited preferential growth inhibition of low-Nm23-expressing, metastatically aggressive cell lines with a Pearson correlation coefficient of ≤0.64. Characterization of one compound, NSC 645306, is presented including in vivo activity in a hollow fiber assay. The data demonstrate a novel approach to drug identification for aggressive human tumors.
Cite this article
Freije, J., Lawrence, J., Hollingshead, M. et al. Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines. Nat Med 3, 395–401 (1997). https://doi.org/10.1038/nm0497-395
